secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2021-07-21T23:59:59+00:00
Accession:  0001485003-21-000152
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio appoints two new directors with regulatory and clinical expertise
---------------------------------------------------------------------------

- Peter K Honig, MD (former Pfizer global regulatory head) and Michael A.S. Jewett, MD (urologic oncologist and Order of Canada) elected to Board.
- Board size increased from 5 to 7 members; both appointed effective July 20, 2021.
- Each new director received initial option to purchase 185,000 shares at $3.86 per share.
- Company reiterates on track for FDA decision on Vicineum BLA by PDUFA date August 18, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500321000152/0001485003-21-000152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500321000152/sesn-20210720.htm
  HTML page:      https://secwatch.observer/filing/0001485003-21-000152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer